Skip to main content
Premium Trial:

Request an Annual Quote

CST, AstraZeneca Extend Phosphorylation-based Biomarker Hunt

NEW YORK, (GenomeWeb News) - Cell Signaling Technology said today it has agreed to extend an agreement with AstraZeneca, under which the drugmaker will continue to use its technology to identify biomarkers for targeted compounds.
This is the fourth such agreement ( ) between the companies. CST said it will continue using its PhosphoScan technology to provide AstraZeneca with phosphorylation profiles of target kinases for an antibody development program that the companies are performing together under a parallel agreement.
CST Director of Business Development Christopher Bunker said the Danville, Mass.-based company will translate information it finds using the PhosphoScan into biomarker assays for AstraZeneca.
Financial terms of the agreement were not released.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.